Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Long-Term Debt Repayments (2023 - 2025)

HCW Biologics (HCWB) has disclosed Long-Term Debt Repayments for 3 consecutive years, with -$31391.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Long-Term Debt Repayments fell 6.2% year-over-year to -$31391.0, compared with a TTM value of -$125786.0 through Sep 2025, down 6.89%, and an annual FY2024 reading of -$119398.0, down 211.96% over the prior year.
  • Long-Term Debt Repayments was -$31391.0 for Q3 2025 at HCW Biologics, down from -$30925.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at -$8981.0 in Q3 2023 and bottomed at -$32460.0 in Q1 2025.
  • Average Long-Term Debt Repayments over 3 years is -$28049.7, with a median of -$29706.0 recorded in 2024.
  • Peak annual rise in Long-Term Debt Repayments hit 5.87% in 2024, while the deepest fall reached 229.13% in 2024.
  • Year by year, Long-Term Debt Repayments stood at -$29292.0 in 2023, then dropped by 5.87% to -$31010.0 in 2024, then dropped by 1.23% to -$31391.0 in 2025.
  • Business Quant data shows Long-Term Debt Repayments for HCWB at -$31391.0 in Q3 2025, -$30925.0 in Q2 2025, and -$32460.0 in Q1 2025.